Dr. Ann Leen is an immunologist with more than 20 years of experience in developing and testing novel T cell therapies for the treatment of cancer and viral infections in immunocompromised patients. She has characterized the immune response to a range of viruses that cause morbidity and mortality in allogeneic hematopoietic stem cell transplant recipients and devised and clinically
implemented immunotherapeutic strategies to treat patients with Adenovirus, BK virus, cytomegalovirus, Epstein Barr virus and Human Herpesvirus 6 infections. She is currently the principal investigator (PI) on 5 investigator-initiated Investigational New Drug (IND) studies and over the past 10 years has served as PI on >10 clinical trials using “first in man” cell therapies for patients.